학술논문
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Document Type
Article
Author
Kümmel, Sherko; Paepke, Stefan; Huober, Jens; Schem, Christian; Untch, Michael; Blohmer, Jens Uwe; Eiermann, Wolfgang; Gerber, Bernd; Hanusch, Claus; Hilfrich, Jörn; Jackisch, Christian; Schneeweiss, Andreas; Denkert, Carsten; Engels, Knut; Klare, Peter; Fasching, Peter A.; von Minckwitz, Gunter; Burchardi, Nicole; Loibl, Sibylle
Source
In European Journal of Cancer October 2017 84:1-8
Subject
Language
ISSN
0959-8049